← Back to Screener
Lexicon Pharmaceuticals, Inc. (LXRX)
Price$1.84
Favorite Metrics
Price vs S&P 500 (26W)26.08%
Price vs S&P 500 (4W)13.41%
Market Capitalization$752.03M
All Metrics
Book Value / Share (Quarterly)$0.30
P/TBV (Annual)3.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)692.66%
Cash Flow / Share (Quarterly)$-0.19
Price vs S&P 500 (YTD)59.10%
Gross Margin (TTM)99.45%
Net Profit Margin (TTM)-101.08%
EPS (TTM)$-0.14
10-Day Avg Trading Volume2.05M
EPS Excl Extra (TTM)$-0.14
Revenue Growth (5Y)15.72%
EPS (Annual)$-0.14
ROI (Annual)-31.16%
Gross Margin (Annual)99.45%
Net Profit Margin (5Y Avg)-29324.68%
Cash / Share (Quarterly)$0.26
Revenue Growth QoQ (YoY)-79.31%
ROA (Last FY)-27.21%
Revenue Growth TTM (YoY)60.24%
EBITD / Share (TTM)$-0.11
ROE (5Y Avg)-107.73%
Operating Margin (TTM)-98.21%
Cash Flow / Share (Annual)$-0.19
P/B Ratio6.99x
P/B Ratio (Quarterly)3.89x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)15.50x
Net Interest Coverage (TTM)-5.04x
ROA (TTM)-22.03%
EV / EBITDA (TTM)17.58x
EPS Incl Extra (Annual)$-0.14
Current Ratio (Annual)4.88x
Quick Ratio (Quarterly)4.73x
3-Month Avg Trading Volume2.57M
52-Week Price Return250.94%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.11
P/S Ratio (Annual)15.10x
Asset Turnover (Annual)0.27x
52-Week High$1.86
Operating Margin (5Y Avg)-28966.14%
EPS Excl Extra (Annual)$-0.14
CapEx CAGR (5Y)59.46%
Tangible BV CAGR (5Y)-7.47%
26-Week Price Return30.07%
Quick Ratio (Annual)4.73x
13-Week Price Return57.63%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)4.88x
Enterprise Value$771.71
Revenue / Share Growth (5Y)-8.73%
Asset Turnover (TTM)0.22x
Book Value / Share Growth (5Y)-23.17%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.07x
Pretax Margin (Annual)-101.08%
Cash / Share (Annual)$0.26
3-Month Return Std Dev93.61%
Gross Margin (5Y Avg)98.08%
Net Income / Employee (TTM)$-1
ROE (Last FY)-46.81%
Net Interest Coverage (Annual)-5.04x
EPS Basic Excl Extra (Annual)$-0.14
P/FCF (TTM)44.26x
Receivables Turnover (TTM)17.01x
Total Debt / Equity (Quarterly)0.50x
EPS Incl Extra (TTM)$-0.14
Receivables Turnover (Annual)17.01x
ROI (TTM)-26.94%
P/S Ratio (TTM)15.10x
Pretax Margin (5Y Avg)-29324.68%
Revenue / Share (Annual)$0.14
Tangible BV / Share (Annual)$1.11
Price vs S&P 500 (52W)221.11%
Year-to-Date Return61.74%
5-Day Price Return5.68%
EPS Normalized (Annual)$-0.14
ROA (5Y Avg)-57.63%
Net Profit Margin (Annual)-101.08%
Month-to-Date Return19.23%
Cash Flow / Share (TTM)$-0.76
EBITD / Share (Annual)$-0.11
Operating Margin (Annual)-98.21%
LT Debt / Equity (Annual)0.46x
ROI (5Y Avg)-68.66%
LT Debt / Equity (Quarterly)0.46x
EPS Basic Excl Extra (TTM)$-0.14
P/TBV (Quarterly)3.09x
P/B Ratio (Annual)3.89x
Inventory Turnover (TTM)1.07x
Pretax Margin (TTM)-101.08%
Book Value / Share (Annual)$0.30
Price vs S&P 500 (13W)56.94%
Beta1.08x
P/FCF (Annual)6.61x
Revenue / Share (TTM)$0.14
ROE (TTM)-41.94%
52-Week Low$0.48
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LXRXLexicon Pharmaceuticals, Inc. | 15.10x | 60.24% | 99.45% | — | $1.84 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics. Its pipeline includes LX9211 and LX9851, oral drug candidates, with LX9851 targeting obesity and associated cardiometabolic disorders. The company focuses on commercializing treatments for significant unmet medical needs.